Contributing Member of the Healthcare Councils

GLG News by this Author

A new treatment for a major problem.

September 30, 2009

Analysis of:ACC: Device May Prevent Stroke in AF Patients | www.medpagetoday.com

Atrial fibrillation is a very common condition that significantly increase the risk of stroke, especially in the older population. Vitamin K antagonists are the only current effective treatment in the higher risk population to reduce stroke. Any new treatment has a huge potential to help reduce risk, and there is nothing else on the horizon to treat this condition.

How much market will MADIT-CRT drive?

September 30, 2009

Analysis of:Cardiac-Resynchronization Therapy for the Prevention of Heart Failure Events | content.nejm.org

While this trial had a positive endpoint, it was not a mortality endpoint.   A major defect is a lack of a medical therapy alone arm.  That said, prevention of heart failure episodes is a laudable goal and given the expense to the US system of CHF, this could be a worthwhile treatment, however the number of patients to benefit will be quite small.

A long way to go...

November 13, 2006

Analysis of:Emisphere Technologies Demonstrates Safety and Efficacy of Oral Insulin in Phase 2 Trial in Type 2 Diabetics | www.emisphere.com

Good proof of concept
Needs lots more data
Cost of final product will be key

 

Post-market surveillance will be tough

November 13, 2006

Analysis of:FDA pledges tougher scrutiny on medical device market | www.boston.com

Post market surveillance is tough for medical devices
Funding to do it right is going to be very expensive

 

Continued good news for Torcetrapib

November 10, 2006

Analysis of:Pfizer Updates Preliminary Results Of Torcetrapib/Atorvastatin Clinical Trials As Abstract For Phase 3 Study Is Released | www.medicalnewstoday.com

- Effective lipid modification (HDL raising and LDL lowering) shown.
- Outcomes data (mortality) still needed
- Lower side effects make torcetrapib attractive

Page : 11 to 5 of 5